1-3 of 3
Christian Kuffer
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design

Mark Roschewski, David M. Kurtz, Jason Westin, Ryan C. Lynch, Charles Macaulay, Christian Kuffer, Gregory J. Hogan, Sandra Close, Jacob J. Chabon, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh, Andre Schultz
Journal: Blood
Blood (2022) 140 (Supplement 1): 785–786.
https://doi.org/10.1182/blood-2022-167936
Published: 2022
Journal Articles

Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP

David M. Kurtz, Gregory J. Hogan, Andre Schultz, Katerina Kopeckova, Christian Kuffer, Derek Blair, Steve Wagner, Sandra Close, Maximilian Diehn, Jacob J. Chabon, Ash A. Alizadeh, Jason Westin
Journal: Blood
Blood (2022) 140 (Supplement 1): 3498–3499.
https://doi.org/10.1182/blood-2022-168378
Published: 2022
Journal Articles

Disease Kinetics Measured By Circulating Tumor DNA Correlates with Treatment Response after Tafasitamab in Combination with R-CHOP with or without Lenalidomide in First Line Treatment of DLBCL

Mouhamad Khouja, Anke Schilhabel, Michaela Kotrova, Monika Brüggemann, Christian Kuffer, Derek Blair, Nikos Darzentas, Christiane Pott
Journal: Blood
Blood (2021) 138 (Supplement 1): 3498.
https://doi.org/10.1182/blood-2021-153176
Published: 2021